新型抗血小板药普拉格雷

普拉格雷是噻吩吡啶类口服抗血小板药的一个新成员.大鼠单次口服普拉格雷对血小板聚集的抑制作用分别约为噻氯匹定的10倍和氯吡格需的100倍.普拉格雷口服后30 min即可见明显的抗血小板聚集效应并持续72 h,提示其起效迅速H作用持久.普拉格雷与阿司匹林联合应用的抗血小板聚集和抑制血栓形成的作用明显优于单独治疗.在心血管病患者中进行的临床研究证实,普拉格雷的抗血小板效应优于氯吡格雷.因此,普拉格雷是一种高效的抗血小板和抗血栓形成药,有望成为治疗动脉粥样硬化性血栓形成和其他缺血性血管病的有效于段.

Prasugrel: a novel antiplatelet agent

Prasugrel is a member of the thienopyridine class of oral antiplatelet agents.A single oral administration of prasugrel produced a dose-related inhibition of platelet aggrega-tion in rats that was approximately 10 and 100 fold more potent than that of clopidogrel and ticiopidine, respectively. The antiaggregatory effect of prasugrei was evident at 30 minutes and lasted until 72 hours after dosing, indicating fast onset and long duration of action. Combined administration of prasugrel with aspirin produced substantially greater inhibition of both platelet aggregation and thrombus formation compared with each agent alone. Clinical studies in patients with cardiovascular disease confirmed the potent antiplatelet effect of prasugrel compared with ciopidogrel. Prasugrei is a highly effective antiplatelet and antithrombotic agent and is anticipa-ted to be effective in the treatment of atherothrombotic and other ischemic vascular diseases.